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PLong-Term Outcomes by Clopidogrel
Duration and Stent Type in a Diabetic
Population With De Novo Coronary Artery Lesions
Somjot S. Brar, MD,* John Kim, MD,† Simerjeet K. Brar, BS,† Ray Zadegan, MD,† Michael Ree, BS,†
In-Lu A. Liu, MS,‡ Prakash Mansukhani, MD,† Vicken Aharonian, MD,† Ric Hyett, BS,†
Albert Yuh-Jer Shen, MD†§
New York, New York; and Los Angeles and Pasadena, California
Objectives The purpose of this study was to determine whether long-term clinical outcomes differed between bare-metal
stents (BMS) and drug-eluting stents (DES) by duration of clopidogrel use among diabetic patients.
Background There is concern that DES are associated with late adverse events such as death and myocardial infarction (MI)
secondary to stent thrombosis. However, data on outcomes in diabetic patients remain limited.
Methods We identified 749 patients with diabetes mellitus who underwent stent implantation with either BMS (n  251)
or DES (n  498) from October 2002 to December 2004. We performed survival analysis on the full cohort and
on those event-free from death, MI, or repeat revascularization at 6 months (n  671).
Results By clopidogrel duration, the event rate for death or MI was 3.2% in the 9-month group, 9.4% in the 6- to
9-month group, and 16.5% in the 6-month group, p  0.001. For death alone, the event rate was 0.5% in the
9-month group, 4.3% in the 6- to 9-month group, and 10.0% in the 6-month group, p  0.001. When taking
BMS clopidogrel non-users as a referent in the multivariate analysis, the hazard ratio (95% confidence interval
[CI]) for death and nonfatal MI for DES clopidogrel users, DES clopidogrel nonusers, and BMS clopidogrel users
were: HR 0.22 (95% CI 0.08 to 0.62, p  0.005), HR 0.39 (95% CI 0.13 to 1.13, p  0.08), and HR 0.25 (95%
CI 0.08 to 0.81, p  0.02), respectively.
Conclusions Longer duration of clopidogrel use was associated with a lower incidence of death or MI in both the BMS and
DES groups. Among clopidogrel nonusers, the incidence of death/MI or death did not differ by stent
type. (J Am Coll Cardiol 2008;51:2220–7) © 2008 by the American College of Cardiology Foundation














iiabetes mellitus is present in 25% of patients undergoing
ercutaneous coronary intervention (PCI) (1). It is a major
isk factor for coronary artery disease and a long-recognized
redictor of restenosis after balloon angioplasty and stent
lacement (2,3). Characterized by neointimal hyperplasia,
estenosis is more common in the diabetic population and
an take a malignant course requiring multiple percutaneous
rocedures or coronary artery bypass grafting (CABG) (4).
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2, 2007, accepted January 6, 2008.urrently, drug-eluting stents (DES) are considered by
any as the standard of care for diabetic patients undergo-
ng PCI. Both the pivotal U.S. trials, the SIRIUS
Sirolimus-coated BX Velocity Balloon-Expandable Stent
n the Treatment of Patients with De Novo Coronary
rtery Lesions) trial and the TAXUS-IV (Polymer-Based
aclitaxel-Eluting Stent in Patients with Coronary Artery
isease) trial, demonstrated efficacy in the diabetic sub-
roups (5,6). However, concern has been raised that the
See page 2228
avorable results among the diabetic subgroups in these
rials might not be generalizable (7,8). Several recent reports
ave shown a greater incidence of late stent thrombosis with
ES when compared with bare-metal stents (BMS) (9–
2). Multiple predictors of stent thrombosis have been
dentified, with the strongest predictor being premature
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June 10, 2008:2220–7 Stent Type and Clopidogrel Duration After PCIerm outcomes with DES compared with BMS, adjusted for
lopidogrel use, in patients with diabetes remain unknown.
We performed an observational study exploring the
elationship between stent type and clopidogrel use with
ong-term death and nonfatal myocardial infarction (MI) in
diabetic population undergoing PCI for de novo lesions.
ethods
tudy population. The study cohort consisted of consec-
tive diabetic patients who underwent initial PCI at the
egional Cardiac Catheterization Laboratory located at the
aiser Permanente Los Angeles Medical Center from
ctober 1, 2002, to December 31, 2004. Diabetes mellitus
as defined as any of the following: use of oral hypoglyce-
ic agents or insulin, fasting plasma glucose values 126
g/dl, or a random plasma glucose concentration 200
g/dl. Measuring a repeat fasting or random plasma glu-
ose on a subsequent day confirmed the diagnosis of
iabetes. Kaiser Permanente is an integrated pre-paid health
lan providing comprehensive care to more than 3 million
embers in Southern California. The health plan owns and
perates medical centers, ambulatory care facilities, phar-
acies, and laboratories.
All patients in this cohort underwent first time PCI
nd received either a BMS or DES. Exclusion criteria
ncluded: prior CABG, patient receiving both a BMS and
ES during the index procedure, moderate to severe
alvular disease, and nonhealth plan member because
ollow-up data were not available. Kaiser Permanente
outhern California Institutional Review Board approval
as received with waiver of the requirement for written
nformed consent.
ata collection. BASELINE DEMOGRAPHIC DATA. Base-
ine demographic data were obtained for review from the
atients’ medical record and health plan databases. For each
atient, data on the distribution of coronary disease, blood
ressure, body mass index, stent size, diameter, site of stent
eployment, other medical history, and procedural data
ere obtained from health plan databases. Laboratory data
hat included serum creatinine, fasting low-density lipopro-
ein, and hemoglobin A1c were obtained at the time of
ardiac catheterization or the most recent value before the
rocedure.
EDICATION USE. Medication use was obtained by review
f prescription records through an electronic pharmacy
rescription database. The number of prescriptions filled,
he daily dose, and the number of pills dispensed for each
rescription beginning on the day of discharge after index
CI were used to calculate the duration of clopidogrel use.
ll patients received 75 mg daily of clopidogrel. Adjunctive
harmacotherapy with beta-blockers, statins, angiotensin-
onverting enzyme inhibitors (ACEIs), and angiotensin II
eceptor blockers (ARBs) were also determined by elec-
ronic pharmacy prescription records. Use of these adjunc-
ive medications was defined as 1 or more prescriptions for Cach drug after the PCI date.
spirin use was not available
hrough the electronic prescrip-
ion database. However, all pa-
ients are instructed to take as-
irin 325 mg daily for 30 days
nd then 81 mg daily indefi-
itely regardless of stent type.
TUDY END POINTS. The pri-
ary end point of the study was
composite of all-cause death
nd nonfatal MI. Vital status was
btained from the medical
ecord, health plan databases, and MORTLINK, which is a
eath database of the residents of California maintained by
he state. Follow-up MI data were obtained by chart review
nd diagnosed by the patient’s physician. We also used
nternational Classification of Disease-9th Revision-
linical Modification (ICD-9-CM) codes for MI to iden-
ify additional possible events in health plan databases. Any
dditional cases identified were then reviewed for confirma-
ion. If troponin I was elevated in the appropriate clinical
ontext (e.g., angina, anginal equivalent, or electrocardio-
ram with consistent abnormalities), then MI was con-
rmed. Periprocedural MI was defined as a creatine kinase-
yocardial band (CK-MB) elevation 3 times the upper
imit of normal.
roup assignments. The cohort was divided into DES
nd BMS groups, depending on the type of stent received.
ach patient might have received more than 1 stent of the
ame class (DES or BMS). For this study both paclitaxel-
nd sirolimus-eluting stents were considered together in the
ES group. The groups were then further divided on the
asis of the duration of clopidogrel use. Clopidogrel users
ere those with continued use for180 days from the index
CI date, whereas nonusers were those who stopped clopi-
ogrel by 180 days.
Left-censored survival analysis was used to determine
hether there were differences in the primary outcome
etween the DES and BMS groups stratified by clopidogrel
se after the 6-month landmark. All patients who suffered
eath, MI, or underwent repeat revascularization (CABG
r PCI) within 6 months of the index PCI were excluded.
he remaining patients were categorized into 4 groups by
tent type and clopidogrel duration: DES with clopidogrel,
ES without clopidogrel, BMS with clopidogrel, and BMS
ithout clopidogrel.
tatistical analysis. Continuous variables were reported as
eans  SD or median and interquartile range if the
istribution was not normally distributed. Normality was
ested by the Shapiro-Wilk test. The analysis of variance
est was used for normally distributed variables. The serum
reatinine and cumulative stent length were non-normally





ARB  angiotensin II
receptor blocker
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
DES  drug-eluting stent(s)
PCI  percutaneous
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Stent Type and Clopidogrel Duration After PCI June 10, 2008:2220–7ute values with comparisons made with the chi-square test
r Fisher exact test where appropriate.
The Kaplan-Meier method was used to construct
urvival curves for the primary end point of death or
onfatal MI and censored for loss of health plan mem-
ership. Comparison between groups was made with the
og-rank test. The left-censored survival analysis was
rom 6 months (180 days) to 18 months (545 days) after
CI. Cox-regression analysis for the primary end point
as also performed. Variables with a p value 0.1 were
ntered into the multivariate model, yielding hazard
atios (HRs) and 95% confidence intervals (CIs). All tests
re 2-tailed, with differences reported as significant if
 0.05. All analyses were performed with SAS statis-
ical software (version 9.1, SAS Institute, Cary, North
arolina).
esults
tudy population. A total of 749 consecutive patients met
ll study criteria at the time of PCI. Of these, 41 died,
uffered nonfatal MI, or underwent revascularization, and
or 37 patients clopidogrel data were not available, leaving
71 in the 6-month left-censored survival analysis. All
opulation characteristics (Table 1) are reported for the
eft-censored analysis cohort. There were 919 stents im-
lanted in the study cohort. The mean age was 62.7  10.8
ears. The DES with clopidogrel group was slightly younger,
1.5  10.2 (p  0.02). The indication for the procedure,
nsulin use and hemoglobin A1c, a measure of glycemic
ontrol, were similar among all groups. Low-density lipopro-
ein levels and adjunctive medical therapy (e.g., statins, beta-
lockers, ACEI/ARB) were higher among clopidogrel users in
oth the DES and BMS groups compared with clopidogrel
onusers. All groups were similar in the distribution of coro-
ary vessels stented and number of significantly diseased
rteries (70% stenosis of a major epicardial coronary artery).
owever, cumulative stent length was greater in the DES
roups. In the BMS groups, 97% of the stents were placed by
pril 2004, which is when the TAXUS DES (Boston Scien-
ific, Natick, Massachusetts) received Food and Drug Admin-
stration (FDA) approval.
lopidogrel compliance. Of the 749 patients, 37 (5%) were
xcluded because there was no available data on clopidogrel use
n the health plan pharmacy records. The mean duration of
lopidogrel use was 9.7 months. Duration of use was slightly
reater among the DES groups (10.1 months) compared with
he BMS groups (9.0 months), p  0.03.
urvival analysis. The Kaplan-Meier analysis for the full
ohort (n  749) is shown in Figure 1. In the first 180 days
fter PCI, the cumulative incidence of death and nonfatal MI
as similar between the BMS and DES groups. However,
fter 180 days the event rate was lower in the DES group (p
.05). A similar but nonsignificant trend was observed for
ortality between the 2 stent types (p  0.33). rIn the left-censored analysis, freedom from death and
onfatal MI was determined for all 4 groups (Fig. 2). For
ES (n  450) compared with BMS (n  221) the
umulative incidence of death or nonfatal MI was 3.1%
ersus 6.2% (p  0.08), respectively. When stratified by
lopidogrel status, the incidence in the BMS group was
reatest among clopidogrel nonusers (12.2%) compared
ith users (3.5%), p  0.01. Among the DES group, the
umulative incidence was 5.5% for clopidogrel nonusers
ompared with 2.2% for users, p  0.07. Among clopi-
ogrel nonusers, the incidence was 5.5% in the DES group
nd 12.2% in the BMS group, p  0.11.
Freedom from death was also determined for all 4 groups
Fig. 3). For the DES group the incidence of death was
.8% compared with 3.6% for the BMS group (p  0.18).
mong the BMS group, clopidogrel user versus nonuser
ncidence of death was 2.0% versus 6.8% (p 0.07). Among
he DES group, clopidogrel user versus nonuser incidence of
eath was 1.0% versus 3.9% (p  0.03). The incidence of
eath in clopidogrel nonusers was 3.9% in the DES group
nd 6.8% in the BMS group (p  0.41).
lopidogrel duration and outcomes. The cumulative in-
idence of death or nonfatal MI was also assessed by
lopidogrel duration. The full study cohort was divided into
groups by duration of clopidogrel use: 6 months, 6 to 9
onths, and 9 months. The event rate for death or MI
as 3.2% in the 9-month group, 9.4% in the 6- to
-month group, and 16.5% in the6-month group (p 0.001)
Fig. 4). For death alone, the event rate was 0.5% in the
9-month group, 4.3% in the 6- to 9-month group, and
0.0% in the 6-month group (p  0.001).
Among the patients who suffered death or MI during the
eft-censored analysis period, 82% were no longer clopi-
ogrel users at the time of the event. The mean  SD in
ays between clopidogrel cessation and death or MI was
88 127 days and not significantly different between stent
roups (p  0.12).
ultivariate analysis. In the Cox regression analysis we
alculated both the unadjusted and adjusted HRs for death
nd nonfatal MI. As previously described, the adjusted
odels included variables that were different among the 4
roups at a p value 0.1. This included adjunctive medical
herapy with statins, beta-blockers, ACEI, ARB, number of
tents deployed, stent diameter, and cumulative stent
ength. In the unadjusted model, taking BMS clopidogrel
onusers as a referent, the HRs and 95% CIs for DES with
lopidogrel, DES without clopidogrel, and BMS with
lopidogrel were HR 0.18 (95% CI 0.07 to 0.49, p 
.001), HR 0.47 (95% CI 0.17 to 1.25, p  0.13), and HR
.26 (95% CI 0.09 to 0.78, p  0.02), respectively. In the
djusted model, taking BMS clopidogrel nonusers as refer-
nt, the values for DES with clopidogrel, DES without
lopidogrel, and BMS with clopidogrel were HR 0.22 (95%
I 0.08 to 0.62, p 0.005), HR 0.39 (95% CI 0.13 to 1.13,
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June 10, 2008:2220–7 Stent Type and Clopidogrel Duration After PCIWe also performed pairwise multivariate adjusted analysis
or the DES and BMS groups for clopidogrel user versus
onuser. In the unadjusted model, the HR and 95% CI for
lopidogrel user versus nonuser in the DES group was HR
.39 (95% CI 0.14 to 1.11, p 0.08) and in the BMS group
as HR 0.27 (95% CI 0.09 to 0.79, p  0.02). In the
opulation Characteristics





Age, yrs 61.5 10.2 63.3 1
Female, % (n) 30.1 (100) 33.9 (43)
Indication, % (n)
Stable angina 19.5 (63) 19.1 (24)
Unstable angina 36.8 (119) 46.8 (59)
NSTEMI 29.4 (95) 27.0 (34)
STEMI 14.2 (46) 7.1 (9)
Prior MI, % (n) 55.7 (180) 58.3 (74)
Insulin, % (n) 20.7 (67) 31.5 (40)
HgA1c, % (n) 7.4 1.7 7.3 1
LDL (mg/dl) 114 37 103 3
Creatinine (mg/dl) 1.0 (0.8–1.1) 1.0 (0.9–
Hemoglobin (mg/dl) 13.5 1.7 13.3 2
Ejection fraction (%) 0.61 0.15 0.62 0
Body mass index (kg/m2) 30.7 6.2 30.1 5
AoSBP, mm Hg 144 31 148 2
AoDBP, mm Hg 71 12 72 1
Clopidogrel duration, % (n)
6 months 71.8 (323) 0
9 months 55.3 (249) 0
Other medications, % (n)
Statins 96.6 (312) 89.8 (114
Beta-blockers 93.5 (302) 86.6 (110
ACEI or ARB 93.2 (301) 83.5 (106
Angiographic variables
No. of stents 1.4 0.6 1.3 0
Mean stent diameter (mm) 2.9 0.3 3.0 0
Cumulative stent length (mm) 23 (18–33) 20 (16–
No. of diseased vessels
1-vessel disease 58.8 (190) 63.0 (80)
2-vessel disease 32.8 (106) 29.9 (38)
3-vessel disease 8.4 (27) 7.1 (9)
Stent location, % (n)
LAD 50.5 (163) 44.9 (57)
Diagonal* 4.0 (13) 1.6 (2)
Circumflex 16.4 (53) 19.7 (25)
Obtuse marginal 9.9 (32) 8.7 (11)
RCA 28.8 (93) 30.7 (39)
PDA or PLV* 3.1 (10) 3.9 (5)
Ramus intermediate* 0.9 (3) 2.4 (3)
Stent use by year
2002 0 0
2003 36.9 (113) 15.4 (47)
2004 68.9 (210) 26.2 (80)
ata are reported as mean  SD, median (range), or % (n). *Comparison made with Fisher exact
ACEI angiotensin-converting enzyme inhibitor; AoDBP aortic diastolic blood pressure; AoSBP
drug-eluting stent(s); HgA1c  hemoglobin A1c; LAD  left anterior descending; LDL  low-den
DA  posterior descending artery; PLV  posterior lateral branch; RCA  right coronary artery; Sultivariate adjusted analysis these were HR 0.48 (95% CI d.16 to 1.47, p  0.48) and HR 0.21 (95% CI 0.06 to 0.73,
 0.01) for the DES and BMS groups, respectively.
iscussion
n this observational study the extended use of clopidogrel,
grel BMS With Clopidogrel
(n  147)
BMS Without Clopidogrel
(n  74) p Value
64.3 10.2 64.0 11.6 0.02
29.9 (44) 36.5 (27) 0.72
0.32
18.5 (27) 18.9 (14)
48.0 (70) 37.8 (28)
23.3 (34) 28.4 (21)
10.3 (15) 14.9 (11)
55.1 (81) 64.9 (48) 0.50
20.4 (30) 27.0 (20) 0.07
7.6 1.8 7.6 1.9 0.40
121 39 111 41 0.001
1.0 (0.8–1.1) 1.0 (0.8–1.2) 0.36
13.3 1.7 13.0 1.7 0.09
0.63 0.15 0.59 0.16 0.55
30.0 5.9 29.4 5.9 0.23
146 33 142 32 0.36
71 14 67 12 0.03
66.5 (147) 0 0.16
48.9 (108) 0 0.12
95.9 (141) 82.4 (61) 0.0001
92.5 (136) 87.8 (65) 0.08
92.5 (136) 83.8 (62) 0.003
1.4 0.6 1.5 0.7 0.03
3.2 0.5 3.0 0.5 0.0001
16 (13–26) 18 (15–26) 0.0001
0.65
58.5 (86) 59.5 (44)
28.6 (42) 32.4 (24)
12.9 (19) 8.1 (6)
42.2 (62) 41.9 (31) 0.27
2.7 (4) 0 (0) 0.25
20.4 (30) 18.9 (14) 0.71
10.2 (15) 12.2 (9) 0.89
35.4 (52) 31.1 (23) 0.56
2.7 (4) 8.1 (6) 0.23
0 (0) 1.4 (1) 0.20
51.0 (30) 49.0 (29)
35.0 (107) 12.8 (39)
3.0 (9) 2.0 (6)
tic systolic blood pressure; ARB angiotensin II receptor blocker; BMS bare-metal stent(s); DES
protein; MI  myocardial infarction; NSTEMI  non–ST-segment elevation myocardial infarction;
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Stent Type and Clopidogrel Duration After PCI June 10, 2008:2220–7ith significantly greater freedom from death and MI in the
MS group (p  0.01) and from death in the DES group
p  0.03). Among clopidogrel nonusers, a group at high
isk for late stent thrombosis, the event rate for death and
I was similar in the DES and BMS groups (p  0.11).
Figure 1 Outcomes by Stent Type
Cumulative incidence of death and nonfatal myocardial infarction or death only
by stent type for the full cohort (n  749). BMS  bare-metal stent(s); DES  dru
Figure 2 Left-Censored Survival Analysis for Death and Nonfata
Cumulative rates of death and nonfatal myocardial infarction by stent type and cloortality was also similar in the DES without clopidogrel
roup compared with the BMS without clopidogrel group
p  0.40). These observations suggest that the extended
se of clopidogrel is associated with a reduction in death or
eath and nonfatal MI. This observed benefit likely results
ng stent(s).
cardial Infarction
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June 10, 2008:2220–7 Stent Type and Clopidogrel Duration After PCIrom the dual action of clopidogrel—the prevention of stent
hrombosis but also clinical events at other sites in the
oronary tree.
In contrast to our observations, 2 prior 6-month left-
ensored survival analyses show increased death and nonfa-
al MI with DES compared with BMS among clopidogrel
onusers (14,15). However, this study relates specifically to
atients with diabetes, whereas in the prior studies the
ajority of the patients (70% to 80%) were not diabetic.
he biologic response to DES might be altered in the
iabetic compared with the nondiabetic patient, which
ight explain, in part, the difference between studies. For
xample, an in vitro study shows that rapamycin does not
eem to impair smooth muscle migration to the same degree
n a hyperglycemic environment compared with an eugly-
emic environment (16), which might account for the
reater late loss observed in diabetic patients. This might
ead to higher rates of endothelialization and thus lower
ates of late stent thrombosis in diabetic patients. This
ight also explain, in part, the higher rates of target lesion
evascularization observed in diabetic patients in clinical
rials. It remains unclear the extent to which other potential
echanisms such as hypersensitivity or inflammatory reac-
ions to the stent polymer, tissue factor expression leading to
Figure 3 Left-Censored Survival Analysis for Death
Cumulative rates of death by stent type and clopidogrel use in the left-censored suprothrombotic environment, late stent malapposition due To thrombus resolution, or stent strut fracture occur in
iabetic patients and result in adverse events (17–20).
lopidogrel use. There are no clinical trial data that
ddress the required duration of clopidogrel use after DES
lacement. The FDA approved DES with 3 to 6 months of
lopidogrel therapy, the protocol-specified minimum dura-
ion in the CYPHER (Cordis Corporation, Miami Lakes,
lorida) and TAXUS stent pivotal trials, respectively (5,6).
ecent data suggest that longer duration of clopidogrel use
ight be necessary given the slight increase in stent throm-
osis observed with DES. However, prolonged use needs to
e balanced against the bleeding risk (21) and cost associ-
ted with clopidogrel therapy. In this study, the incidence of
eath and MI by clopidogrel duration was determined. In
oth the full cohort and the left-censored analysis cohort the
xtended use of clopidogrel was associated with a decrease in
eath and the composite of death and nonfatal MI (p 
.01). These results complement those of the CREDO
Clopidogrel for the Reduction of Events During Observa-
ion) trial (22), and PCI CURE (PCI in the Clopidogrel in
nstable Angina to Prevent Recurrent Ischemic Events)
rial (23).
Patients in this study were insured health plan members.
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Stent Type and Clopidogrel Duration After PCI June 10, 2008:2220–7onfatal MI and long-term prognosis. Compliance with
lopidogrel as measured by prescriptions filled was 95
ercent. This is in contrast to the observation in the
REMIER (Prospective Registry Evaluating Myocardial
nfarction: Events and Recovery) registry that almost 1 in 7
atients were no longer taking a thienopyridine by 30 days
24). This is important, because premature discontinuation
f clopidogrel has been identified as the most powerful
redictor of stent thrombosis (13). The compliance in our
opulation might have even been greater than reported,
ecause internal health plan data show that up to 5% of the
ealth plan members receive medications at nonhealth plan
harmacies. However, we were not able to account for this
n our estimates. All patients before discharge receive a
ritten list of medications and a follow-up appointment
Figure 4 Outcomes by Clopidogrel Duration
(A and B) Cumulative incidence of death and nonfatal myocardial infarction or dea
cohort (n  749). (C and D) Cumulative incidence of death and nonfatal myocardiith a cardiologist in 1 to 4 weeks, which might also bontribute to the overall compliance with medical therapy
nd improved outcomes with DES use.
tudy limitations. This was an observational analysis, and
lopidogrel use was not randomly assigned. The decision to
ontinue beyond the FDA label specifications might be
orrelated with unidentified prognostic factors or institu-
ional biases. After the introduction of the TAXUS DES in
he U.S. we routinely recommended a minimum of 6
onths of clopidogrel to all patients regardless of DES type.
econd, we assumed persons refilling prescriptions were
ontinuously taking clopidogrel. The largest quantity dis-
ensed was 90 tablets, requiring patients to return to the
harmacy for additional medication. However, we did not
erform pill counts, which could more accurately reflect
edication use. Nevertheless, using prescription records has
y by clopidogrel duration for the full
rction or death only by clopidogrel duration in the left-censored analysis.th onl
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June 10, 2008:2220–7 Stent Type and Clopidogrel Duration After PCIf medication use, because self-reporting is limited by recall
nd other biases (25,26). Third, aspirin use was not available
hrough the pharmacy prescription database, and our inabil-
ty to adjust for aspirin noncompliance remains a limitation.
owever, given that clopidogrel was typically used on
verage for several months, it is likely that patients were also
ompliant with aspirin therapy. All patients receive the same
nstructions for aspirin use as previously stated. Lastly,
eft-censored analysis can create a potential bias due to the
ossible differential truncation of patients before the cen-
oring point. In contrast, the cumulative incidence analyses
o not suffer from such bias and yield cumulative incidence
f death or death and MI from the index PCI date.
onclusions
atients with diabetes require a multifaceted approach with
isk factor modification and contemporary medical and
nterventional therapy to target both progression of coro-
ary disease and the culprit lesion. Our data suggest that
ith contemporary medical therapy the extended use of
lopidogrel was associated with fewer adverse events in the
MS and DES groups. Among clopidogrel nonusers, a
roup at high risk for stent thrombosis, the event rates for
eath and MI were similar in the DES and BMS groups.
owever, definite conclusions on the safety and efficacy of
ES and the appropriate duration of clopidogrel use in a
iabetic population can only be drawn from prospective
andomized trials.
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